M2 Archive: Preview
You haven't logged in. If you have archive credits in your account, please log in now to use them. If not, you can buy credits in our shopping area.
Five Prime Therapeutics Inc partners with Adimab for therapeutic monoclonal antibodies
Biotechnology company Five Prime Therapeutics Inc (NasdaqGS:FPRX) reported on Thursday a sponsored research collaboration agreement for therapeutic monoclonal antibodies.
The company has signed the agreement with Adimab LLC, a provider of monoclonal and bispecific antibodies.
If you want to view the full text of this story, you must first purchase archive credits. Return to Archives